​

Capricor Therapeutics (CAPR) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

CAPR Stock Forecast

Capricor Therapeutics (CAPR) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $10.63, with a high of $25.00 and a low of $3.50. This represents a 23.03% increase from the last price of $8.64.

- $5 $10 $15 $20 $25 High: $25 Avg: $10.63 Low: $3.5 Last Closed Price: $8.64

CAPR Stock Rating

Capricor Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (80.00%), 2 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 2 8 Strong Sell Sell Hold Buy Strong Buy

CAPR Price Target Upside V Benchmarks

TypeNameUpside
StockCapricor Therapeutics23.03%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1413
Avg Price Target$25.00$10.63$35.58
Last Closing Price$8.64$8.64$8.64
Upside/Downside189.35%23.03%311.81%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26-27--9
Aug, 26--10--10
Jul, 2628---10
Jun, 2627---9
May, 2627---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 01, 2026Edward TenthoffPiper Sandler$25.00$9.91152.27%189.35%
Jul 29, 2026Cantor Fitzgerald$3.50$6.57-46.73%-59.49%
Jul 28, 2026Industrial Alliance Securities$7.00$7.00--18.98%
Jul 27, 2026Roth Capital$7.00$7.00--18.98%
May 15, 2026Boobalan PachaiyappanRoth Capital$38.00$29.8127.47%339.81%
Mar 13, 2026Kristen KluskaCantor Fitzgerald$62.00$33.4285.52%617.59%
Dec 15, 2025UBS$50.00$26.1291.42%478.70%
Dec 10, 2025Piper Sandler$45.00$27.3864.35%420.83%
Dec 08, 2025Oppenheimer$54.00$26.89100.82%525.00%
Dec 04, 2025Maxim Group$50.00$25.1898.57%478.70%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 01, 2026Piper SandlerNeutralOverweightupgrade
Aug 25, 2026OppenheimerPerformOutperformupgrade
Aug 24, 2026H.C. WainwrightNeutralNeutralhold
Aug 14, 2026Cantor FitzgeraldNeutralOverweightupgrade
Jul 30, 2026OppenheimerOutperformPerformdowngrade
Jul 30, 2026H.C. WainwrightBuyNeutraldowngrade
Jul 30, 2026Piper SandlerOverweightNeutraldowngrade
Jul 29, 2026Cantor FitzgeraldOverweightNeutraldowngrade
Jul 28, 2026Alliance Global PartnersBuyNeutraldowngrade
Jul 27, 2026Roth CapitalBuyNeutraldowngrade

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 $4 $5 $6 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.87$-1.18$-0.83$-1.15$-2.26---
Avg Forecast$-0.80$-1.22$-1.04$-1.19$-0.98$0.41$1.25$3.48
High Forecast$-0.58$-0.59$-0.87$-0.64$2.04$1.63$2.20$5.07
Low Forecast$-0.96$-2.51$-1.21$-1.35$-1.90$-1.20$-0.94$2.07
Surprise %8.75%-3.28%-20.19%-3.36%130.61%---

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$244.90K$2.55M$25.18M$22.27M----
Avg Forecast$222.50K$1.59M$21.05M$20.97M$44.47M$113.29M$184.74M$287.81M
High Forecast$257.35K$2.89M$28.47M$21.45M$60.14M$113.29M$189.52M$389.25M
Low Forecast$175.05K$960.35K$14.47M$20.66M$30.58M$113.29M$179.97M$197.92M
Surprise %10.07%60.00%19.62%6.21%----

Net Income Forecast

$-150M $-90M $-30M $30M $90M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-20.02M$-29.02M$-22.29M$-40.47M$-105.04M---
Avg Forecast$-21.42M$-32.58M$-27.85M$-34.11M$-40.14M$18.31M$16.87M$93.10M
High Forecast$-15.48M$-15.73M$-23.31M$-17.12M$54.74M$43.65M$58.91M$135.75M
Low Forecast$-25.79M$-67.10M$-32.39M$-36.08M$-50.88M$-32.13M$-25.17M$55.30M
Surprise %-6.54%-10.93%-19.97%18.63%161.68%---

CAPR Forecast FAQ

Is Capricor Therapeutics stock a buy?

Capricor Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Capricor Therapeutics is a favorable investment for most analysts.

What is Capricor Therapeutics's price target?

Capricor Therapeutics's price target, set by 10 Wall Street analysts, averages $10.63 over the next 12 months. The price target range spans from $3.5 at the low end to $25 at the high end, suggesting a potential 23.03% change from the previous closing price of $8.64.

How does Capricor Therapeutics stock forecast compare to its benchmarks?

Capricor Therapeutics's stock forecast shows a 23.03% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Capricor Therapeutics over the past three months?

  • September 2026: 0% Strong Buy, 22.22% Buy, 77.78% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Capricor Therapeutics’s EPS forecast?

Capricor Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $0.41, marking a -118.14% decrease from the reported $-2.26 in 2025. Estimates for the following years are $1.25 in 2027, and $3.48 in 2028.

What is Capricor Therapeutics’s revenue forecast?

Capricor Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $113.29M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $184.74M, and $287.81M for 2028.

What is Capricor Therapeutics’s net income forecast?

Capricor Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $18.31M, representing a -117.43% decrease from the reported $-105M in 2025. Projections indicate $16.87M in 2027, and $93.1M in 2028.